1. Home
  2. CYTK vs WTM Comparison

CYTK vs WTM Comparison

Compare CYTK & WTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • WTM
  • Stock Information
  • Founded
  • CYTK 1997
  • WTM 1980
  • Country
  • CYTK United States
  • WTM Bermuda
  • Employees
  • CYTK N/A
  • WTM N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • WTM Property-Casualty Insurers
  • Sector
  • CYTK Health Care
  • WTM Finance
  • Exchange
  • CYTK Nasdaq
  • WTM Nasdaq
  • Market Cap
  • CYTK 4.6B
  • WTM 4.4B
  • IPO Year
  • CYTK 2004
  • WTM N/A
  • Fundamental
  • Price
  • CYTK $58.45
  • WTM $1,912.85
  • Analyst Decision
  • CYTK Buy
  • WTM
  • Analyst Count
  • CYTK 16
  • WTM 0
  • Target Price
  • CYTK $76.73
  • WTM N/A
  • AVG Volume (30 Days)
  • CYTK 2.0M
  • WTM 36.7K
  • Earning Date
  • CYTK 11-05-2025
  • WTM 11-05-2025
  • Dividend Yield
  • CYTK N/A
  • WTM 0.05%
  • EPS Growth
  • CYTK N/A
  • WTM N/A
  • EPS
  • CYTK N/A
  • WTM 79.93
  • Revenue
  • CYTK $85,738,000.00
  • WTM $2,578,600,000.00
  • Revenue This Year
  • CYTK $363.61
  • WTM N/A
  • Revenue Next Year
  • CYTK $64.08
  • WTM N/A
  • P/E Ratio
  • CYTK N/A
  • WTM $23.93
  • Revenue Growth
  • CYTK 2635.74
  • WTM 12.16
  • 52 Week Low
  • CYTK $29.31
  • WTM $1,648.00
  • 52 Week High
  • CYTK $63.86
  • WTM $2,023.00
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.20
  • WTM 60.71
  • Support Level
  • CYTK $58.84
  • WTM $1,891.26
  • Resistance Level
  • CYTK $63.86
  • WTM $1,939.50
  • Average True Range (ATR)
  • CYTK 2.52
  • WTM 42.23
  • MACD
  • CYTK -0.26
  • WTM 11.11
  • Stochastic Oscillator
  • CYTK 47.43
  • WTM 90.86

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About WTM White Mountains Insurance Group Ltd.

White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations.

Share on Social Networks: